Abstract
Trioxaquine PA1259 is an efficient drug on larval- and adult-stage schistosomes, able to alkylate heme inside the treated worms, leading to the formation of covalent heme-drug adducts. Such mechanism, similar to that one reported for other trioxaquines in Plasmodium, indicates that heme may be a common target of these trioxane-based drugs in different blood-feeding parasites.